Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND1 | P24385 | 19/20 | 0.65 |
| ▸ | CDK2 | P24941 | 17/20 | 0.65 |
| ▸ | CDK4 | P11802 | 16/20 | 0.65 |
| ▸ | CCND2 | P30279 | 12/20 | 0.65 |
| ▸ | CCND3 | P30281 | 12/20 | 0.65 |
| ▸ | CCNA2 | P20248 | 10/20 | 0.65 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.65 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.65 |
| ▸ | FGFR4 | P22455 | 6/20 | 0.65 |
| ▸ | FGFR3 | P22607 | 6/20 | 0.65 |
| ▸ | CCNA1 | P78396 | 8/20 | 0.62 |
| ▸ | CCNE1 | P24864 | 12/20 | 0.59 |
| ▸ | CCNE2 | O96020 | 5/20 | 0.59 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.59 |
| ▸ | CDK1 | P06493 | 3/20 | 0.59 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.59 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.59 |
| ▸ | PAK4 | O96013 | 1/20 | 0.56 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.56 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6807752 | 0.88 | CCND1 (0.73) | CCND1CDK2CDK4CCND2CCND3 | |
| SCHEMBL5265457 | 0.83 | CCND1 (0.79) | CCND1CDK2CDK4CCND2CCND3 | |
| SCHEMBL5264679 | 0.83 | CCND1 (0.79) | CCND1CDK2CDK4CCND2CCND3 | |
| SCHEMBL6812932 | 0.83 | CCND1 (0.61) | CCND1CDK2CDK4CCND2CCND3 | |
| SCHEMBL6808407 | 0.79 | CDK4 (0.64) | CCND1CDK2CDK4CCND2CCND3 | |
| SCHEMBL5263407 | 0.79 | CDK4 (1.00) | CCND1CDK2CDK4CCND2CCND3 | |
| SCHEMBL6804918 | 0.79 | CCND1 (0.73) | CCND1CDK2CDK4CCND2CCND3 | |
| SCHEMBL6808989 | 0.79 | CDK4 (0.63) | CCND1CDK2CDK4CCND2CCND3 | |
| SCHEMBL5262469 | 0.78 | CDK4 (1.00) | CCND1CDK2CDK4CCND2CCND3 | |
| SCHEMBL5262750 | 0.78 | CDK4 (1.00) | CCND1CDK2CDK4CCND2CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040224958-A1 | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | BOOTH RICHARD JOHN (US) | 2004-11-11 | — | — | US | claimed |
| EP-1255755-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2002-11-13 | — | — | EP | claimed |
| WO-2001055148-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | claimed |
| US-20040224958-A1 | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | BOOTH RICHARD JOHN (US) | 2004-11-11 | — | — | US | disclosed |
| EP-1255755-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001055148-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224958-A1 | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | CDK4, CDKL1, CCNT1 | CCND1 23/4885CDK2 11/4885CDK4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.